These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19697757)

  • 21. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of globalization on vaccine development and availability.
    Milstien JB; Kaddar M; Kieny MP
    Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What are today's orphaned vaccines?
    Wilde H
    Clin Infect Dis; 2001 Sep; 33(5):648-50. PubMed ID: 11486287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The landscape of vaccines in China: history, classification, supply, and price.
    Zheng Y; Rodewald L; Yang J; Qin Y; Pang M; Feng L; Yu H
    BMC Infect Dis; 2018 Oct; 18(1):502. PubMed ID: 30286735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine supply: a cross-national perspective.
    Danzon PM; Pereira NS; Tejwani SS
    Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
    Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
    Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine procurement and self-sufficiency in developing countries.
    Woodle D
    Health Policy Plan; 2000 Jun; 15(2):121-9. PubMed ID: 10837034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The problems and promise of vaccine markets in developing countries.
    Batson A
    Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
    Beall RF; Kuhn R; Attaran A
    Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
    Plahte J
    Lancet Infect Dis; 2005 Jan; 5(1):58-63. PubMed ID: 15620562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obstacles to developing vaccines for the Third World.
    Robbins A; Freeman P
    Sci Am; 1988 Nov; 259(5):126-33. PubMed ID: 3212439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.